LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Novartis AG

Fermé

109.54 1.09

Résumé

Variation du prix de l'action

24h

Actuel

Min

108.06

Max

109.58

Chiffres clés

By Trading Economics

Revenu

786M

3.6B

Ventes

62M

14B

P/E

Moyenne du Secteur

17.077

56.602

BPA

2.28

Rendement du dividende

3.67

Marge bénéficiaire

26.476

Employés

75,883

EBITDA

643M

5.8B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-1.35% downside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.67%

2.45%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-765M

217B

Ouverture précédente

108.45

Clôture précédente

109.54

Score Technique

By Trading Central

Confiance

Bearish Evidence

Novartis AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mai 2025, 09:36 UTC

Principaux Mouvements du Marché

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 avr. 2025, 16:35 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 avr. 2025, 11:55 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 avr. 2025, 11:54 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire Regulus in $1.7 Billion Deal

29 avr. 2025, 07:09 UTC

Résultats

Novartis Lifts Guidance After Profit, Sales Top Views -- Update

29 avr. 2025, 05:36 UTC

Résultats

Novartis Lifts Guidance After Profit, Sales Top Views

12 mai 2025, 22:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

30 avr. 2025, 11:40 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 avr. 2025, 11:39 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire Regulus in $1.7B Deal

30 avr. 2025, 11:16 UTC

Acquisitions, Fusions, Rachats

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 avr. 2025, 11:15 UTC

Acquisitions, Fusions, Rachats

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 avr. 2025, 11:14 UTC

Acquisitions, Fusions, Rachats

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 avr. 2025, 11:13 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Regulus Therapeutics

29 avr. 2025, 12:34 UTC

Market Talk
Résultats

Novartis Solid Result Shifts Investor Focus to 2H -- Market Talk

29 avr. 2025, 11:54 UTC

Market Talk
Résultats

Correction to Novartis Market Talk

29 avr. 2025, 11:47 UTC

Market Talk
Résultats

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

29 avr. 2025, 10:42 UTC

Market Talk
Résultats

Novartis Surprises With Another Beat & Raise -- Market Talk

29 avr. 2025, 10:16 UTC

Market Talk
Résultats

Novartis's Guidance Lift Reflects Strong Sales -- Market Talk

29 avr. 2025, 05:06 UTC

Résultats

Novartis Had Seen Core Operating Profit to Grow at High Single to Low Double-Digit in 2025 at Constant Currencies

29 avr. 2025, 05:06 UTC

Résultats

Novartis Expects Core Operating Profit to Grow Low Double-Digit in 2025 at Constant Currencies

29 avr. 2025, 05:05 UTC

Résultats

Novartis Had Seen Sales Grow Mid- to High-Single Digit in 2025 at Constant Currencies

29 avr. 2025, 05:04 UTC

Résultats

Novartis Expects Sales to Grow High Single Digit in 2025 at Constant Currencies

29 avr. 2025, 05:02 UTC

Résultats

Novartis Raises 2025 View

29 avr. 2025, 05:02 UTC

Résultats

Analysts Had Seen Novartis 1Q Rev $13.00B

29 avr. 2025, 05:02 UTC

Résultats

Novartis 1Q Rev $13.23B

29 avr. 2025, 05:01 UTC

Résultats

Analysts Had Seen Novartis 1Q Core Operating Profit EUR5.22B

29 avr. 2025, 05:01 UTC

Résultats

Novartis 1Q Core Operating Profit EUR5.575B

29 avr. 2025, 05:00 UTC

Résultats

Novartis AG 1Q Adj EPS $2.28

29 avr. 2025, 05:00 UTC

Résultats

Novartis AG 1Q EPS $1.83

Comparaison

Variation de prix

Novartis AG prévision

Objectif de Prix

By TipRanks

-1.35% baisse

Prévisions sur 12 Mois

Moyen 107 USD  -1.35%

Haut 116 USD

Bas 88 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

2

Achat

2

Maintien

1

Vente

Score Technique

By Trading Central

N/A / 112.63Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.